Creative Planning’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Creative Planning’s Portfolio IMUC Stock Details IMUC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-150	Closed	–	–	5167
2016 Q4	$0	Buy	+150	New	+$476	﹤0.01%	5120
2016 Q3	–	Sell	-100	Closed	-$1K	–	4964
2016 Q2	$1K	Sell	100 -10	-9%	-$103	﹤0.01%	4321
2016 Q1	$1K	Buy	110 +10	+10%	+$112	﹤0.01%	4279
2015 Q4	$1K	Buy	+100	New	+$1.65K	﹤0.01%	4370

Other funds holding IMUC

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Creative Planning's IMUC Position: Q1 2017 in Review

Creative Planning sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q1 2017, closing a stake of 150 shares.

Creative Planning first reported a position in IMUC in Q4 2015 and held it in 4 quarters. The position peaked at $1K in Q2 2016. 17 funds tracked by Wall St. Rank hold IMUC as of Q1 2017.

Creative Planning reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q1 2017 after selling out during the quarter.
Creative Planning sold 150 ImmunoCellular Therapeutics, Ltd. shares in Q1 2017.
Creative Planning first reported a position in ImmunoCellular Therapeutics, Ltd. in Q4 2015 and held it in 4 quarters.
Creative Planning's ImmunoCellular Therapeutics, Ltd. position peaked at $1K in Q2 2016.
17 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q1 2017.

Based on Creative Planning's 13F filing for Q1 2017, filed 7 Apr 2017.